Immunotherapy drug shows promise in keeping lung cancer at bay

NCT ID NCT03706690

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether the immunotherapy drug durvalumab can help people with stage III non-small cell lung cancer that hasn't grown after chemoradiation. About 400 participants receive either durvalumab or a placebo every 4 weeks. The goal is to see if durvalumab delays cancer progression and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: durvalumab (an immunotherapy drug)
What this could lead to: If successful, this could offer a new standard treatment to help keep stage III lung cancer from growing after initial chemoradiation.
What could go wrong: This is a late-stage trial, but durvalumab may not work for everyone and can cause immune-related side effects. Results may not apply to all lung cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

407 people

The number who actually took part.

Started

Nov 2018

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age≥18 years 2. Documented NSCLC and present with locally advanced, unresectable (Stage III) disease; 3. Receipt of concurrent or sequential chemoradiation therapy, 4. No progression following definitive, platinum-based, concurrent or sequential chemoradiation therapy 5. World Health Organization (WHO) PS of 0 or 1; 6. No prior exposure to any anti CTLA-4, anti-PD-1, anti-PD-L1, or anti PD L2 antibodies, excluding therapeutic anticancer vaccines 7. Adequate organ and marrow function required 8. Life expectancy of at least 12 weeks 9. Tumor PD-L1 status, with the Ventana SP263 PD-L1 IHC assay determined by a reference laboratory, must be known prior to randomization. 10. Tumour sample requirements are as follows: Provision of a tumour tissue sample (newly acquired sample \<=3 months old is preferred, but an archived sample \<=6 months old is acceptable) in a quantity sufficient to allow for analysis. Exclusion Criteria: 1. History of allogeneic organ transplantation, or another primary malignancy, or active primary immunodeficiency. 2. Active or prior documented autoimmune or inflammatory disorders 3. Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent 4. Active infection including tuberculosis hepatitis B hepatitis C (HCV), or human immunodeficiency virus (positive human immunodeficiency virus \[HIV\] 1/2 antibodies). 5. Mixed small cell and NSCLC histology, sarcomatoid variant 6. Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 from the prior chemoradiation therapy. 7. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. 8. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung

Contacts and locations

Locations

Research Site

Beijing, 100021, China
Research Site

Beijing, 100142, China
Research Site

Beijing, 100730, China
Research Site

Beijing, 100853, China
Research Site

Bengbu, 233004, China
Research Site

Changchun, 130000, China
Research Site

Changchun, 510000, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610041, China
Research Site

Chengdu, 610042, China
Research Site

Chengdu, 610072, China
Research Site

Chongqing, 400037, China
Research Site

Fuzhou, 350011, China
Research Site

Guangzhou, 510280, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310006, China
Research Site

Hangzhou, 310022, China
Research Site

Harbin, 150081, China
Research Site

Linhai, 317000, China
Research Site

Nanjing, 210009, China
Research Site

Nanning, 530021, China
Research Site

Ningbo, 315010, China
Research Site

Qingdao, 266042, China
Research Site

Shanghai, 200030, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200433, China
Research Site

Shenyang, 110042, China
Research Site

Ürümqi, 830000, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430030, China
Research Site

Yangzhou, 225001, China
Research Site

Zhengzhou, 450000, China
Research Site

Zhengzhou, 450008, China
Research Site

Hong Kong, 00000, Hong Kong
Research Site

Bangalore, 560068, India
Research Site

Bengaluru, 560076, India
Research Site

Karamsad, 388325, India
Research Site

Kolkata, 700160, India
Research Site

Nashik, 422005, India
Research Site

Vadodara, 390007, India
Research Site

Culiacán, 80230, Mexico
Research Site

Mexico City, 0 3100, Mexico
Research Site

Mexico City, 11810, Mexico
Research Site

México, 1400, Mexico
Research Site

Monterrey, 64000, Mexico
Research Site

San Luis Potosí City, 78250, Mexico
Research Site

Bacolod, 6100, Philippines
Research Site

Baguio City, 2600, Philippines
Research Site

Cagayan de Oro, 9000, Philippines
Research Site

Cebu, 6000, Philippines
Research Site

Davao City, 8000, Philippines
Research Site

Quezon City, 1100, Philippines
Research Site

Quezon City, 1104, Philippines
Research Site

San Juan City, 1502, Philippines
Research Site

Bialystok, 15-540, Poland
Research Site

Gdansk, 80-952, Poland
Research Site

Poznan, 60-569, Poland
Research Site

Tomaszów Mazowiecki, 97-200, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Kazan, Tatarstan, 420029, Russia
Research Site

Kirov, 610021, Russia
Research Site

Moscow, 115478, Russia
Research Site

Moscow, 121467, Russia
Research Site

Murmansk, 183047, Russia
Research Site

Novosibirsk, 630055, Russia
Research Site

Novosibirsk, 630099, Russia
Research Site

Obninsk, 249036, Russia
Research Site

Saint Petersburg, 197758, Russia
Research Site

Samara, 443031, Russia
Research Site

Saransk, 430005, Russia
Research Site

Volgograd, 400138, Russia
Research Site

Daegu, 41944, South Korea
Research Site

Gwangju, 61469, South Korea
Research Site

Seoul, 08308, South Korea
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 70403, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

Taipei, 114, Taiwan
Research Site

Taipei, 235, Taiwan
Research Site

Taoyuan, 333, Taiwan
Research Site

Adana, 01060, Turkey (Türkiye)
Research Site

Ankara, 06340, Turkey (Türkiye)
Research Site

Edirne, 22030, Turkey (Türkiye)
Research Site

Istanbul, 34030, Turkey (Türkiye)
Research Site

Konya, 42080, Turkey (Türkiye)
Research Site

Malatya, 44100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.